Simonidesova Simona, Hamsikova Eva, Ludvikova Viera, Klozar Jan, Vencalek Ondrej, Tachezy Ruth
Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
J Surg Oncol. 2019 Aug;120(2):117-124. doi: 10.1002/jso.25473. Epub 2019 Apr 15.
The presence of human papillomavirus (HPV)-specific antibodies in patients with head and neck cancer at enrollment has prognostic significance. In cervical carcinoma patients, the decrease of HPV E6/E7-specific antibodies appears to be associated with a better prognosis.
This prospective study with follow-up focused on the persistence and prognostic value of antibodies specific for HR HPV-derived VLPs and HPV16 E6/E7 oncoproteins in patients with oropharyngeal cancers. In this study, we analyzed sera of 93 patients taken a year after the end of treatment and sera from 58 of these patients taken up to 14 years after treatment.
The level of HPV-specific antibodies decreased on the 1-year follow-up and the decrease during the long follow-up was statistically significant. For HPV16 E7 antibodies the decrease was steeper in nonrecurrent patients. While the level of antibodies at enrollment was not predictive of recurrences, the decrease of HPV16 E6 antibodies at 1-year follow up was associated with better overall as well as disease-specific survival of patients.
The data suggest that the pretreatment level of HPV-specific antibodies is not predictive of the occurrence of recurrences but the decrease HPV16 E6 antibodies on the 1-year follow-up is predictive of better survival of HN patients.
头颈癌患者在入组时人乳头瘤病毒（HPV）特异性抗体的存在具有预后意义。在宫颈癌患者中，HPV E6/E7特异性抗体的减少似乎与较好的预后相关。
这项有随访的前瞻性研究聚焦于口咽癌患者中针对高危型人乳头瘤病毒（HR HPV）衍生的病毒样颗粒（VLPs）和HPV16 E6/E7癌蛋白的特异性抗体的持久性和预后价值。在本研究中，我们分析了93例患者在治疗结束一年后采集的血清以及其中58例患者在治疗后长达14年采集的血清。
HPV特异性抗体水平在1年随访时下降，且在长期随访期间的下降具有统计学意义。对于HPV16 E7抗体，在无复发患者中下降更为明显。虽然入组时的抗体水平不能预测复发，但1年随访时HPV16 E6抗体的下降与患者更好的总生存以及疾病特异性生存相关。
数据表明，HPV特异性抗体的预处理水平不能预测复发的发生，但1年随访时HPV16 E6抗体的下降可预测头颈癌患者更好的生存。
